Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 17, Issue 18, Pages 2417-2429
Publisher
Informa UK Limited
Online
2016-11-09
DOI
10.1080/14656566.2016.1258060
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Secretase-Independent and RhoGTPase/PAK/ERK-Dependent Regulation of Cytoskeleton Dynamics in Astrocytes by NSAIDs and Derivatives
- (2017) Mathieu P. Lichtenstein et al. JOURNAL OF ALZHEIMERS DISEASE
- Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors
- (2016) Genevieve Evin BIODRUGS
- AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
- (2016) Susanna Eketjäll et al. JOURNAL OF ALZHEIMERS DISEASE
- Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates
- (2016) Mihirbaran Mandal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Alzheimer Disease
- (2016) Mark E. Jentoft et al. MAYO CLINIC PROCEEDINGS
- Endogenous APP accumulates in synapses after BACE1 inhibition
- (2016) Saket Milind Nigam et al. NEUROSCIENCE RESEARCH
- Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
- (2016) Francesco Panza et al. Biomed Research International
- Fyn inhibition rescues established memory and synapse loss in Alzheimer mice
- (2015) Adam C. Kaufman et al. ANNALS OF NEUROLOGY
- Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer’s Disease
- (2015) Arun K. Ghosh et al. ChemMedChem
- Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance
- (2015) Arnold Bakker et al. NeuroImage-Clinical
- Effects of oral ELND005 (scyllo-inositol) on neuropsychiatric symptoms in a 78-week phase 2 study in mild/moderate Alzheimer's disease (AD): Potential role of myo-inositol reduction
- (2014) Constantine Lyketsos et al. Alzheimers & Dementia
- CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609
- (2014) Bruce Albala et al. Alzheimers & Dementia
- MONITORING THE SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA (SAPPA) AND BETA (SAPPB) FRAGMENTS IN PLASMA AND CSF FROM HEALTHY INDIVIDUALS TREATED WITH BACE INHIBITOR AZD3293 IN A MULTIPLE ASCENDING DOSE STUDY: PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATE
- (2014) Kina Höglund et al. Alzheimers & Dementia
- Lessons from a Failed γ-Secretase Alzheimer Trial
- (2014) Bart De Strooper CELL
- Inhibition of Amyloid-β Aggregation in Alzheimer's Disease
- (2014) Qiuming Wang et al. CURRENT PHARMACEUTICAL DESIGN
- AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration
- (2014) Robert Alexander et al. NEUROBIOLOGY OF AGING
- Clinical trial of an inhibitor of RAGE-A interactions in Alzheimer disease
- (2014) D. Galasko et al. NEUROLOGY
- The A4 Study: Stopping AD Before Symptoms Begin?
- (2014) R. A. Sperling et al. Science Translational Medicine
- BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
- (2014) Robert Vassar Alzheimers Research & Therapy
- Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF
- (2013) Francois Bernier et al. Alzheimers & Dementia
- Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
- (2013) Sandra Sivilia et al. BMC NEUROSCIENCE
- CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
- (2013) Joel Ross et al. Current Alzheimer Research
- A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment
- (2013) Bruce H. Morimoto et al. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation
- (2013) Alex Crowe et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- International Work Group Criteria for the Diagnosis of Alzheimer Disease
- (2013) Jeffrey L. Cummings et al. MEDICAL CLINICS OF NORTH AMERICA
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012
- (2013) Nathan Herrmann et al. Alzheimers Research & Therapy
- Neuropathological Alterations in Alzheimer Disease
- (2013) A. Serrano-Pozo et al. Cold Spring Harbor Perspectives in Medicine
- Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo
- (2012) Jose A. Morales-Garcia et al. ACS Chemical Neuroscience
- The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration
- (2012) Mark Forman et al. Alzheimers & Dementia
- Novel BACE1 inhibitor, E2609, lowers Aβ levels in the brain, cerebrospinal fluid and plasma in rats and guinea pigs
- (2012) Tatsuto Fukushima et al. Alzheimers & Dementia
- First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing
- (2012) Robert Lai et al. Alzheimers & Dementia
- Amyloid deposition, hypometabolism, and longitudinal cognitive decline
- (2012) Susan M. Landau et al. ANNALS OF NEUROLOGY
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- The National Institute on Aging-Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: predicting the outcome
- (2012) Liang-Hao Guo et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice
- (2012) Kathryn Rogers et al. Molecular Neurodegeneration
- Drug repositioning for Alzheimer's disease
- (2012) Anne Corbett et al. NATURE REVIEWS DRUG DISCOVERY
- Biomarker trajectories across stages of Alzheimer disease
- (2012) Giovanni B. Frisoni Nature Reviews Neurology
- Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment
- (2012) Arnold Bakker et al. NEURON
- Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model
- (2012) P. E. Sanchez et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose
- (2012) Xiao-Jing Sun et al. Neuroscience Bulletin
- Assessment scales in dementia
- (2012) Bart Sheehan Therapeutic Advances in Neurological Disorders
- CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects
- (2011) M. Ewers et al. CEREBRAL CORTEX
- Alternative Mitochondrial Electron Transfer as a Novel Strategy for Neuroprotection
- (2011) Yi Wen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Unknown
- (2011) Daniel Paris et al. MOLECULAR MEDICINE
- Testing the Right Target and Right Drug at the Right Stage
- (2011) R. A. Sperling et al. Science Translational Medicine
- PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease
- (2010) Marwan N. Sabbagh et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease
- (2010) Yakeel T. Quiroz et al. ANNALS OF NEUROLOGY
- Powerful beneficial effects of benfotiamine on cognitive impairment and -amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice
- (2010) X. Pan et al. BRAIN
- Tau in Alzheimer Disease and Related Tauopathies
- (2010) K. Iqbal et al. Current Alzheimer Research
- Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy
- (2010) K. R. Brunden et al. JOURNAL OF NEUROSCIENCE
- Neuropathology of Alzheimer's Disease
- (2010) Daniel P. Perl MOUNT SINAI JOURNAL OF MEDICINE
- Alzheimer's disease: strategies for disease modification
- (2010) Martin Citron NATURE REVIEWS DRUG DISCOVERY
- High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment
- (2010) Michael A. Yassa et al. NEUROIMAGE
- Identifying and validating biomarkers for Alzheimer's disease
- (2010) Christian Humpel TRENDS IN BIOTECHNOLOGY
- Defining and labeling disease-modifying treatments for Alzheimer's disease
- (2009) Jeffrey L. Cummings Alzheimers & Dementia
- The structure and function of Alzheimer’s gamma secretase enzyme complex
- (2009) Sudarsan Krishnaswamy et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
- (2009) L. Serenó et al. NEUROBIOLOGY OF DISEASE
- Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment
- (2009) Ming Teng Koh et al. NEUROPSYCHOPHARMACOLOGY
- Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
- (2008) Dick Terwel et al. AMERICAN JOURNAL OF PATHOLOGY
- A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease
- (2008) Y. Matsuoka et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started